摘要
目的评估马来酸曲美布汀治疗肠易激综合征(IBS)的疗效和安全性.方法采用前瞻性临床研究,予符合罗马Ⅲ标准的62例IBS患者口服马来酸曲美布汀4周。研究包括2周基线期,2周治疗期,4周治疗期和随后的2周随访期。治疗前后分别记录症状并检查肝、肾功能。结果62例IBS患者治疗4周后,总改善率为81.2%,IBS的主要症状明显改善。研究期间未发生明显不良反应。结论马来酸曲美布汀治疗IBS安全有效,值得临床推广。
Objective To evaluate the efficacy and safety of trimebutine maleate in the treatment of IBS.Methods A prospective clinical trial was designed.In accordance with Rome Ⅲ criteria,trimebutine was given to 62 IBS patients orally for 4 weeks.This study was consiste of a 2-week baseline period,a 2-week treatment period,a 4-week treatment period,followed by a 2-week withdras follow-up observation period.The symptoms of IBS were recorded and the liver function and renal function were examined before and after the treatment.Results After a 4-week course treatment,81.2% of the 62 patients were improved.The major symptoms of IBS were ameliorated markedly.No adverse effect was found in this study.Conclusion Trimebutine maleate is an effective and safe medicine for alleviation of IBS symptoms,and worth of further generalization.
出处
《临床消化病杂志》
2010年第1期35-37,共3页
Chinese Journal of Clinical Gastroenterology
关键词
肠易激综合征
马来酸曲美布汀
疗效
安全性
Irritable bowel syndrome
Trimebutine maleate
Treatmentoutcome
Safety
